Figure 2. TAT–NBI1 treatment restores the normoxic phenotype in the LLC–PK1 Hx–Hp/Nx model. LLC–PK1 cells were treated as indicated in Figure 1. The expression of CDK5, p35/p25, cyclin I in total cell extracts was analyzed by western blot in the presence of (A) TAT-NBI1 or (B) roscovitine. An analysis of the phosphorylation levels of ERK1/2, H2A.x ,and Chk1 detected by the western blotting of the cells treated with (C) TAT-NBI1 or (D) roscovitine, respectively. A densitrometric analysis of the western blots from 3 independent experiments are shown in the right-hand panels.